WYGC
0.0602
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
4.90MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Wenyuan Group posted no revenue in Q3 ended September 30, 2025, down from $11,263 y/y, driving a $74,827 operating loss—better than $86,447 last year on lower professional fees, while SG&A rose to $56,727. YTD revenue also zeroed out versus $67,968 prior, with operating loss shrinking to $237,207 from $885,885 after skipping $570,000 share-based comp. Cash drained to $7,608 amid $133,133 operating outflow, offset by $106,146 financing; equity flipped to $(19,836) deficit. Cash funds operations. Litigation reserve hit $266,869 over 2022 office guaranty.
10-Q
Q2 FY2025 results
Wenyuan Group posted zero revenue for Q2 FY2025 ended June 30, 2025, down 100% y/y from $16.3K, while narrowing operating loss to $78.4K from $321.4K on lower professional fees and no share-based comp. YTD H1 net loss shrank to $164.8K from $797K, with operating cash burn easing to $100K versus $244K prior year. Cash dwindled to $961 amid $291K working capital deficit, propped by $51K net shareholder loans and $48K stock issuance. Litigation reserve hit $265K for office guaranty default. Equity barely afloat at -$2K. Losses track shares. Customer concentration looms large.
10-Q
Q1 FY2025 results
Wenyuan Group posted zero revenue for Q1 FY2025 ended March 31, 2025, down 100% y/y from $40,404, with no sales amid weak market demand for cultural and health products. Operating loss narrowed to $84K from $478K y/y, thanks to slashed professional fees ($18K vs $36K) and no share-based comp after $360K last year; net loss hit $86K, close to operating with minor other expenses. Cash dwindled to $312 from $27K q/q, burned $40K in operations, propped by $13K net shareholder loans amid $338K liabilities. Litigation reserve stands at $262K for office guaranty default. Disclosure controls falter.
10-K
FY2024 results
Wenyuan Group posted FY2024 revenue of $60K from new cultural and health product sales via HWAC, up 186% y/y from $21K, while exiting aquaculture (discontinued mid-year after $2.1M 2023 contribution). Q4 saw offline sales momentum with related-party deals, yet net loss widened to $1.17M from $1.03M amid $264K litigation reserve on office guarantee and $501K share-based comp. Cash burn hit $454K operations but eased to $27K end-balance via $670K equity raises. No debt remains post-conversions. PRC oversight could throttle future sales ramps.
10-Q
Q3 FY2024 results
Wenyuan Group posted Q3 revenue of $11.3K from offline cultural and health product sales—up from zero a year ago—yielding $5.2K gross profit, while operating expenses fell to $91.7K from $133.7K, trimming continuing net loss to $85K. YTD revenue jumped 222% to $68K (derived), yet $914K operating expenses drove $886K continuing loss; share-based comp hit $570K. Cash climbed to $154K, bolstered by $657K stock issuances, with third-party debt at $31K (0.5% rate, due in one year). Aquaculture ops shed in March for $3.4K gain. Revenue hinges on two customers.
CFOO
CHINA FOODS HOLDINGS LTD
0.66+0.00
DDC
DDC Enterprise Limited
2.27-0.02
IMG
CIMG Inc.
1.17-0.55
MALG
MICROALLIANCE GROUP INC
1.78+0.00
OCG
Oriental Culture Holding LTD
0.15-0.03
QSJC
Tancheng Group Co., Ltd.
0.21+0.00
WBUY
WEBUY GLOBAL LTD.
1.79+0.01
WNW
Meiwu Technology Company Limite
1.49+0.02
WYHG
Wing Yip Food Holdings Group Li
0.80+0.05
YJ
Yunji Inc. - American Depositor
1.40-0.09